Uno studio per valutare l'efficacia e la sicurezza di Rozanolixizumab nei partecipanti adulti con malattia associata agli anticorpi della mielina oligodendrocita glicoproteina (MOG) (MOG-AD) (cosMOG)
Uno studio cardine randomizzato, in doppio cieco, controllato con placebo, multicentrico, di fase 3 con un periodo di estensione in aperto per valutare l'efficacia e la sicurezza di rozanolixizumab in partecipanti adulti con malattia associata agli anticorpi della glicoproteina mielinica oligodendrocitica (MOG) (MOG- ANNO DOMINI)
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Melbourne, Australia
- Mog001 30022
-
-
-
-
-
Ghent, Belgio
- Mog001 40185
-
-
-
-
-
Porto Alegre, Brasile
- Mog001 60033
-
-
-
-
-
Hradec Králové, Cechia
- Mog001 40195
-
Teplice, Cechia
- Mog001 40721
-
-
-
-
-
Goyang-si, Corea del Sud
- Mog001 20226
-
-
-
-
-
Strasbourg, Francia
- Mog001 40170
-
-
-
-
-
Göttingen, Germania
- Mog001 40140
-
Münster, Germania
- Mog001 40177
-
-
-
-
-
Chiba, Giappone
- Mog001 20068
-
Isehara, Giappone
- Mog001 20307
-
Kitakyushu-shi, Giappone
- Mog001 20049
-
Kodaira, Giappone
- Mog001 20143
-
Koriyama-shi, Giappone
- Mog001 20223
-
Sendai, Giappone
- Mog001 20224
-
Sendai, Giappone
- Mog001 20227
-
Shinjuku-ku, Giappone
- Mog001 20070
-
Suita-shi, Giappone
- Mog001 20032
-
-
-
-
-
Athens, Grecia
- Mog001 40850
-
-
-
-
-
Pavia, Italia
- Mog001 40146
-
Roma, Italia
- Mog001 40629
-
Verona, Italia
- Mog001 40646
-
-
-
-
-
Culiacán, Messico
- Mog001 50486
-
Mexico City, Messico
- Mog001 50485
-
-
-
-
-
Bydgoszcz, Polonia
- Mog001 40840
-
-
-
-
-
Coimbra, Portogallo
- Mog001 40485
-
Porto, Portogallo
- Mog001 40669
-
-
-
-
-
Liverpool, Regno Unito
- Mog001 40661
-
Oxford, Regno Unito
- Mog001 40163
-
-
-
-
-
Barcelona, Spagna
- Mog001 40267
-
Madrid, Spagna
- Mog001 40161
-
Murcia, Spagna
- Mog001 40350
-
Málaga, Spagna
- Mog001 40341
-
Seville, Spagna
- Mog001 40049
-
-
-
-
Arizona
-
Scottsdale, Arizona, Stati Uniti, 85259-5452
- Mog001 50297
-
-
California
-
Palo Alto, California, Stati Uniti, 94304
- Mog001 50450
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Mog001 50101
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20057
- Mog001 50553
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- Mog001 50308
-
-
Illinois
-
Peoria, Illinois, Stati Uniti, 61637
- Mog001 50472
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Mog001 50552
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114-3117
- Mog001 50243
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Mog001 50104
-
-
Texas
-
San Antonio, Texas, Stati Uniti, 78229
- Mog001 50568
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Mog001 50473
-
-
-
-
-
Huddinge, Svezia
- Mog001 40663
-
-
-
-
-
Basel, Svizzera
- Mog001 40723
-
Bern, Svizzera
- Mog001 40337
-
Zurich, Svizzera
- Mog001 40630
-
-
-
-
-
Istanbul, Turchia (Türkiye)
- Mog001 40550
-
Izmir, Turchia (Türkiye)
- Mog001 40726
-
Samsun, Turchia (Türkiye)
- Mog001 40648
-
Sancaktepe, Turchia (Türkiye)
- Mog001 40725
-
-
-
-
-
Kyiv, Ucraina
- Mog001 20319
-
Ternopil, Ucraina
- Mog001 20228
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participant must be ≥18 to ≤89 years of age, at the time of signing the informed consent
- Confirmed diagnosis of MOGAD consistent with published diagnostic criteria for MOGAD
- Participant has history of relapsing MOGAD with at least 1 documented relapse over the last 12 months and a documented positive serum MOG Ab test using a cell-based assay (CBA) within 6 months prior to randomization
- Participant must be clinically stable at the time of the Screening Visit and during the Screening Period
Exclusion Criteria:
- Participant has been diagnosed with a neurological autoimmune disease (including multiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD)), or a systemic autoimmune disease that in the opinion of the investigator can interfere with the safety of the participant
- Participant has a clinically important active infection (including unresolved or not adequately treated infection) as assessed by the investigator, including participants with a serious infection within 6 weeks prior to the first dose of the investigational medicinal product (IMP)
- Participant has a current or medical history of primary immunodeficiency
- Participant tests positive for aquaporin-4 antibodies at Screening
- Participant has a serum total IgG level ≤ 5.5g/L
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Rozanolixizumab Arm
Participants randomized into this arm will receive rozanolixizumab at pre-specified timepoints. |
Participants will receive pre-specified doses of rozanolixizumab.
Altri nomi:
|
|
Comparatore placebo: Placebo Arm
Participants randomized into this arm will receive placebo at pre-specified timepoints to maintain the blinding. |
Participants will receive placebo.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
For Part A: Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment Period
Lasso di tempo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
The TTFR (days) will be defined as the interval between the date of randomization and the first date of the objective relapse. During the Double Blind (DB) Treatment Period (Part A); EDB/EWD = End of Double-Blind/Early Withdrawal Visit |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part B: Incidence of treatment-emergent adverse events (TEAEs) during OLE Treatment Period
Lasso di tempo: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Open-Label Extension (OLE) Treatment Period (Part B); EOS/EWD = End of Study/Early Withdrawal Visit. |
OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
|
For Part B: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP) during OLE Treatment Period
Lasso di tempo: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs leading to discontinuation of the study are reported. |
OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
For Part A: Change from Baseline in Low-Contrast Monocular Visual Acuity (Worst Affected Eye) measured by low-contrast Landolt C Broken Rings Chart at the EDB/EWD Visit
Lasso di tempo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
Visual acuity is a measurement of the capacity for visual discrimination of fine details. Visual acuity tests are used to determine the smallest characters that can be read on a standardized chart. The Landolt C Broken Ring Chart uses standardized incomplete rings or "C", which are positioned in any direction in the chart (up, down, left, right, and 45 degree positions in between). The participant has to be able to indicate where the break of the "C" is located, by describing the position or by giving gesture. |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part A: Disability as assessed by Expanded Disability Status Scale (EDSS) scores at the EDB/EWD Visit (with confirmation at 3 months)
Lasso di tempo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments with half steps from 1.0 to 9.5. The higher the value the higher is the level of impairment and disability. |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part A: Number of MOGAD related inpatient hospitalizations during the DB Treatment Period
Lasso di tempo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
The total number of MOGAD related hospitalizations from Baseline through EDB/EWD Visit. |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part A: Incidence of treatment-emergent adverse events (TEAEs) during the DB Treatment Period
Lasso di tempo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part B: Independently centrally adjudicated annualized relapse rate (ARR) during the DB and OLE Treatment Period
Lasso di tempo: Baseline (Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
An ARR will be calculated for each participant prior to randomization into the Double-Blind Treatment Period (based on available historical data), and 2 ARRs after randomization to study treatment: first for relapses occurring during the Double-Blind Treatment Period and the second for relapses occurring during the OLE Treatment Period. The relapse episodes for each participant will be recorded throughout the entire study. |
Baseline (Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: UCB Cares, 001 844 599 2273
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MOG001
- 2021-000352-19 (Numero EudraCT)
- 2023-509237-39 (Identificatore di registro: EU Clinical Trials)
- U1111-1301-0122 (Altro identificatore: Universal Trial Number (UTN))
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Periodo di condivisione IPD
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Criteri di accesso alla condivisione IPD
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .